Postagens

#ASCO 2017 (ARTEMIS ) A randomized, triple negative breast cancer enrolling trial to confirm molecular profiling improves survival (ARTEMIS).

Imagem
Postar um comentário
Leia mais

#ASCO 2017 Whole exome sequencing of metaplastic breast cancer (MpBC): Effect of mutation status on survival.

Imagem
Postar um comentário
Leia mais

#ASCO 2017 (ERIBULIN +GEMCITABINE METASTATIC BREAST CANCER HER-2 ---) Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).

Imagem
Postar um comentário
Leia mais

#ASCO 2017 LUNA: A randomized phase II trial of liver resection plus chemotherapy or chemotherapy alone in patients with unresectable lung and resectable liver metastases from colorectal adenocarcinoma

Imagem
Postar um comentário
Leia mais

#ASCO 2017 LCCC 1525: Combination immunotherapy with cyclophosphamide plus pembrolizumab in patients with advanced triple negative breast cancer (TNBC).

Imagem
Postar um comentário
Leia mais

#ASCO 2017 ALLIANCE A011502 STAGE 2 or 3 ( NODE POSITIVE HER2--) PLUS ASPIRIN FOR 5 YEARS X PLACEBO

Imagem
Postar um comentário
Leia mais

#ASCO 2017 (ONCOTYPE - TAILORx RESULTS ) The performance of the 21-gene assay standard cutpoints of 18 and 31 in HR+, HER2- invasive breast cancer (BC), while waiting for TAILORx mid-range recurrence score results

Imagem
Postar um comentário
Leia mais